SCHEMBL23749753

SCHEMBL23749753

Cc1cccc(-n2ccsc2=N)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
HPGD P15428 1/20 0.45
HSP90AA1 P07900 1/20 0.40
MGLL Q99685 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
INMT O95050 2/20 0.38
ADRB1 P08588 1/20 0.38
RAB9A P51151 2/20 0.37
KMT2A Q03164 1/20 0.37
ACHE P22303 1/20 0.37
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
GAA P10253 1/20 0.36
GRM1 Q13255 1/20 0.36
PMM2 O15305 1/20 0.36
MPI P34949 1/20 0.36
PHOSPHO1 Q8TCT1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23749751 0.80 ALDH1A1 (0.44) ALDH1A1MGLLADRB1ACHELMNA
SCHEMBL23749752 0.79 MGLL (0.41) ALDH1A1HPGDMGLLADRB1KMT2A
SCHEMBL23749745 0.78 NPC1 (0.47) ALDH1A1MGLLINMTRAB9AKMT2A
SCHEMBL23727071 0.77 INMT (0.41) ALDH1A1INMTRAB9AKMT2A
SCHEMBL23749866 0.74 PARP1 (0.44) L3MBTL1
SCHEMBL23749909 0.73 SMN1; SMN2 (0.36) INMT
SCHEMBL23727418 0.70 CYP2A6 (0.46) ALDH1A1GAA
SCHEMBL23749749 0.68 ALDH1A1 (0.42) ALDH1A1HPGDMGLLINMTADRB1
SCHEMBL23749865 0.67 INMT (0.39) ALDH1A1HPGDMGLLL3MBTL1INMT
SCHEMBL23727376 0.67 ALOX15 (0.44) ALDH1A1MGLLL3MBTL1INMTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617785-B2 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss THE ROCKEFELLER UNIVERSITY (US) 2026-05-05 US disclosed
EP-4100008-B1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS UNIV ROCKEFELLER (US) 2025-04-02 EP disclosed
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 US disclosed
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 US disclosed
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 US disclosed
CN-115515579-A Pyrrolo [2,3-b ] pyridine-3-carboxamide compositions and methods for ameliorating hearing loss 洛克菲勒大学 2022-12-23 CN disclosed
EP-4100008-A1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS The Rockefeller University (US) 2022-12-14 EP disclosed
WO-2021158936-A1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12617785-B2 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss YAP1, LATS2, LATS1 ALDH1A1 2546/4885HPGD 4084/4885HSP90AA1 1372/4885
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS LATS2, LATS1, YAP1 ALDH1A1 3775/4885HPGD 2492/4885HSP90AA1 1993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.